Amendments to the Claims

1. (Currently Amended). A compound having a formula I,



I

or a pharmaceutically acceptable salt ~~salt, solvate, hydrate or stereoisomer~~ thereof, wherein:

A_1 is: CH_2, O or S;

A_2 and A_3 are independently: CH_2, O or S;

E_1, E_2, E_3, E_4 and E_5 are each CH or substituted carbon bearing A_2 or ~~and~~ R^3; or at least one of E_1, E_2, E_3, E_4 and E_5 is nitrogen and each of others being CH or substituted carbon bearing A_2 or ~~and~~ R^3;

Q is: $-C(O)OR^6$;

Y is: a bond or C_1-C_6 alkyl;

Z is: a) phenyl-T-pyridinyl or naphthyl-T-pyridinyl each optionally substituted with one or more R^7; wherein T is a single bond, C, C=O, or O;~~;~~

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

R^1 and R^2 are each independently:

hydrogen,

C_1-C_6 alkyl,

and;

R^3 is: hydrogen,

~~nitro,~~

~~cyano,~~

~~hydroxyl,~~

halo, or

~~haloalkyl,~~

~~haloalkyloxy,~~

~~aryloxy,~~

C_1-C_6 alkyl;~~,~~

~~C_1-C_6 alkoxy, or~~

~~C_3-C_8 cycloalkyl;~~

R^4 and R^5 are each hydrogen;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

;

R^7 is: hydrogen,

~~oxo,~~

~~nitro,~~

~~cyano,~~

~~hydroxyl,~~

halo,

haloalkyl,

haloalkyloxy,

~~aryloxy,~~

~~arylalkyl,~~

~~aminoalkyl,~~

C_1-C_6 alkyl, or

C_1-C_6 alkoxy~~;~~.

~~$(CH_2)_nC_3$-C_8 cycloalkyl,~~

~~$C(O)R^9$;~~

~~$C(O)OR^9$;~~

~~$C(=NOR^8)R^9$;~~

~~$CR^8(OH)R^9$;~~

~~$C[=C(R^8)_2]R^9$;~~

~~OR^9;~~

~~SR^9 or~~

~~$S(O)_pR^9$;~~

~~R^8 is: hydrogen or C_1-C_6 alkyl; and~~

~~R^9 is: hydrogen,~~

~~C_1-C_6 alkyl,~~

~~C_3-C_8 cycloalkyl,~~

~~aryl,~~

~~heteroaryl or~~

~~heterocyclyl,~~

~~wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:~~

~~hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl~~.

2. (Currently Amended). The compound of Claim 1, wherein the compound is represented by a compound of formula II,



II

or a pharmaceutically acceptable salt ~~salt, solvate, hydrate or stereoisomer~~ thereof, wherein:

A_1 is: CH_2, O or S;

A_2 is: O or S or CH_2;

Q is: $-C(O)OR^6$;

Y is: a bond or C_1-C_6 alkyl;

Z is: phenyl-T-pyridinyl or naphthyl-T-pyridinyl each optionally substituted with one or more R^7; wherein T is a single bond, C , C=O, or O;~~,~~

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

R^1 and R^2 are each independently:

hydrogen,

C_1-C_6 alkyl

;

R^3 is: hydrogen,

~~nitro,~~

~~cyano,~~

~~hydroxyl,~~

halo, or

~~haloalkyl,~~

haloalkyloxy,

aryloxy,

C_1-C_6 alkyl,

C_1-C_6 alkoxy, or

C_3-C_8 cycloalkyl;

R^4 and R^5 are each hydrogen;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^7 is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C_1-C_6 alkyl,

C_1-C_6 alkoxy;,

$(CH_2)_nC_3$-C_8 cycloalkyl,

$C(O)R^9$,

$C(O)OR^9$,

$C(=NOR^8)R^9$,

$CR^8(OH)R^9$,

$C[=C(R^8)_2]R^9$,

OR^9,

SR^9 or

~~$S(O)_pR^9$;~~

~~R^8 is: hydrogen or C_1-C_6 alkyl; and~~

~~R^9 is: hydrogen,~~

~~C_1-C_6 alkyl,~~

~~C_3-C_8 cycloalkyl,~~

~~aryl,~~

~~heteroaryl or~~

~~heterocyclyl,~~

~~wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:~~

~~hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl~~.

3. (Currently Amended). The compound of Claim 2, wherein Z is an optionally substituted structural formula selected from following:



wherein T is:

a bond

; and

rings g and h are each optionally substituted with one or more groups independently selected from the group consisting of:

hydrogen~~, oxo, nitro, cyano, hydroxyl~~, halo, haloalkyl, haloalkyloxy,~~ aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$,~~ C_1-C_6 alkyl, and C_1-C_6 alkoxy~~ and $(CH_2)_n$$C_3$-$C_8$ cycloalkyl~~.

4. (Canceled)

5. (Withdrawn). The compound of Claim 2, wherein the compound is represented by structural formula IV,



IV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl;

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) $-S(O)_2$-, -C(=CH_2)-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

6. (Withdrawn). The compound of Claim 5, wherein the compound is represented by structural formula V,



V

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R^1 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, methyl, ethyl, isopropyl, $N(CH_3)_2$, $S(O)_2CH_3$, methoxy and cyclopropyl.

7. (Withdrawn). The compound of Claim 6, wherein the compound is represented by a structural formula VI,



VI

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8. (Canceled)

9. (Canceled)

10. (Currently amended). The compound of Claim 2, wherein the compound is represented by structural formula VIII,



VIII

or a pharmaceutically acceptable salt ~~salt, solvate, hydrate or stereoisomer~~ thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond or -O-, and

ring b is optionally substituted with one or more groups independently selected from:

hydrogen, ~~oxo, nitro, cyano, hydroxyl,~~ halo, haloalkyl, haloalkyloxy, ~~aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$,~~ C_1-C_6 alkyl, and C_1-C_6 alkoxy ~~and $(CH_2)_nC_3$-C_8 cycloalkyl~~.

11. (Currently Amended). The compound of Claim 10, wherein the compound is represented by structural formula IX,



IX

or a pharmaceutically acceptable salt ~~salt, solvate, hydrate or stereoisomer~~ thereof, wherein:

R^1 is C_1-C_3 alkyl;

R^3 is: hydrogen, halo or C_1-C_4 alkyl;

ring b is optionally substituted with one or more groups independently selected from the group consisting of: hydrogen, halo, haloalkyl, haloalkyloxy and C_1-C_6 alkyl.

12. (Currently Amended). The compound of Claim 11, wherein the compound is represented by structural formula X,



X

or a pharmaceutically acceptable salt ~~salt, solvate or hydrate~~ thereof.

13. (Previously Presented). The compound of Claim 11, wherein the compound is represented by structural formula XI,



XI

14. (Withdrawn). The compound of Claim 2, wherein the compound is represented by structural formula XII,



XII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1 or 2;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^4, R^5, R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

rings k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

15. (Canceled)

16. (Currently Amended). The compound of Claim 2, wherein the compound is represented by structural formula XIII,



XIII

or a pharmaceutically acceptable salt ~~salt, solvate, hydrate or stereoisomer~~ thereof, wherein

m is 1, 2, 3, or 4.

17. (Canceled).

18. (Withdrawn). The compound of Claim 16, wherein the compound is represented by structural formula XV,



XV

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R^2 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $N(CH_3)_2$, $S(O)_2CH_3$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

19. (Currently Amended). The compound of Claim 2, wherein the compound is represented by structural formula XVI,



XVI

or a pharmaceutically acceptable salt ~~salt, solvate, hydrate or stereoisomer~~ thereof, wherein Y is a branched alkyl.

20. (Canceled).

21. (Withdrawn). The compound of Claim 19, wherein the compound structural formula XVIII,



XVIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, O or C(O);

R^3 is: methyl or ethyl;

R^{9a} and R^{9b} are each independently hydrogen, methyl or ethyl, wherein at least one of R^{9a} and R^{9b} being methyl or ethyl;

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $S(O)_2CH_3$, $N(CH_3)_2$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

22. (Canceled).

23. (Withdrawn). The compound of Claim 1, wherein the compound is a compound of formula XX,



XX

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 is: a bond, CH_2, O or S, and wherein A_1 and R^4 or A_1 and R^5 together being a 3- to 6-membered carbocyclyl when A_1 is a carbon;

A_2 is: O or S or CH_2;

Q is: $-C(O)OR^6$, or R^{6A};

Y is: a bond, C_1-C_6 alkyl or C_3-C_6 cycloalkyl;

Z is: a) aryl;

b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or

d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R^7;

n is: 1, 2, 3, 4, 5 or 6

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R^1 and R^2 are each independently:

hydrogen,

haloalkyl,

C_1-C_6 alkyl,

$(CH_2)_nC_3$-C_8 cycloalkyl, or

R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R^3 is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C_1-C_6 alkyl,

C_1-C_6 alkoxy, or

C_3-C_8 cycloalkyl;

R^4 and R^5 are each independently: hydrogen or C_1-C_6 alkyl;

R^6 is: hydrogen, C_1-C_6 alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



;

R^7 is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C_1-C_6 alkyl,

C_1-C_6 alkoxy,

$(CH_2)_nC_3$-C_8 cycloalkyl,

$C(O)R^9$,

$C(O)OR^9$,

$C(=NOR^8)R^9$,

$CR^8(OH)R^9$,

$C[=C(R^8)_2]R^9$,

OR^9,

SR^9 or

$S(O)_pR^9$;

R^8 is: hydrogen or C_1-C_6 alkyl; and

R^9 is: hydrogen,

C_1-C_6 alkyl,

C_3-C_8 cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_3-C_8 cycloalkyl.

24. (Canceled).

25. (Canceled).

26. (Withdrawn). The compound of Claim 23, wherein the compound is a compound of structural formula XXII,



XXII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R^1 is: methyl, ethyl or cyclopropyl;

R^3 is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF_3, OCF_3, $S(O)_2CH_3$, $N(CH_3)_2$, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

27. (Withdrawn). The compound of Claim 1, wherein the compound is a compound of structural formula XXIII,



XXIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A_1 and A_2 are respectively:

O and O,

CH_2 and O,

CH_2 and S,

O and S or

S and O;

m is: 1, 2, 3 or 4;

R^1 is: C_1-C_3 alkyl; and

R^3 is: hydrogen, halo or C_1-C_6 alkyl;

R^6 and R^9 are each independently: hydrogen or C_1-C_6 alkyl;

T is: a bond, -O-, -C(O)-, -S(O) $-S(O)_2$-, $-C(=CH_2)$-, -C(=NOH)- or -CH(OH)-; and

rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1-C_6 alkyl, C_1-C_6 alkoxy and $(CH_2)_nC_3$-C_8 cycloalkyl.

28. (Canceled).

29. (Currently Amended). A compound of Claim 1 selected from the group consisting of:

	Structure	Name
29		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
30		{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
31	Chiral 	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
32	Chiral 	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

	Structure	Name
33	 Chiral	3-{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
34	 Chiral	{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
35	 Chiral	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
36	 Chiral	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-ethyl-phenyl}-propionic acid
37	 Chiral	{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

	Structure	Name
38	 Chiral	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
39	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
40	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
41		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
42		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid

	Structure	Name
43		3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
44		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
45	Chiral 	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid
49	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
50	Chiral 	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

	Structure	Name
51	 Chiral	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid
52	 Chiral	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
53	 Chiral	3-{2-Methyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
54	 Chiral	3-{2-Ethyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
55	 Chiral	3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
56	 Chiral	3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

	Structure	Name
57	 Chiral	3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
58	 Chiral	3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
59	 Chiral	3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
90		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
91		{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

	Structure	Name
92	 Chiral	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
93	 Chiral	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
94	 Chiral	3-{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
95	 Chiral	{4-[3-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
96	 Chiral	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid

	Structure	Name
97	 Chiral	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-ethyl-phenyl}-propionic acid
98	 Chiral	{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
99	 Chiral	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
100	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid
101	 Chiral	3-{2-Ethyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-butoxy]-phenyl}-propionic acid

	Structure	Name
102		3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
103		3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
104		3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
105		3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
106	Chiral 	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid

	Structure	Name
110	 Chiral	3-{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
111	 Chiral	{4-[3-(4-Ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
112	 Chiral	3-{2-Ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}-propionic acid
113	 Chiral	3-{4-[3-(4-Chloro-2-pyridin-2-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
114	 Chiral	3-{2-Methyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
115	 Chiral	3-{2-Ethyl-4-[3-(2-pyridin-2-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid

	Structure	Name
116	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
117	Chiral 	3-{4-[3-(4-Chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
118	Chiral 	3-{4-[3-(4-Ethyl-2-pyridin-4-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
119	Chiral 	3-{2-Methyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
120	Chiral 	3-{2-Ethyl-4-[3-(2-pyridin-4-yl-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
141	Chiral 	(R)-3-(4-{3-[4-ethyl-2-(pyridine-2-carbonyl)-phenoxy]-butoxy}-2-methyl-phenyl)-propionic acid

	Structure	Name
175	 Chiral	(R)- 3-{4-[3-(4-chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

30. (Withdrawn). The compound of Claim 29, wherein the compound is

 Chiral

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

31. (Currently Amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 or a pharmaceutically acceptable salt ~~salt, solvate or hydrate~~ thereof.

32. (Canceled).

33. (Canceled).

34. (Canceled).

35. (Canceled).

36. (Canceled).

37. (Canceled).

38. (Canceled).

39. (Canceled).

40. (Canceled).

41. (Canceled).

42. (Canceled).

43. (Previously Presented). A method for lowering blood-glucose in a mammal in need thereof comprising the step of administering an effective amount of a compound of Claim 1.

44. (Canceled).

45. (Canceled).

46. (Canceled).

47. (Canceled).

48. (Canceled).

49. (Canceled)